In 2022, Groupe Chevrillon invested in Astrea Pharma, a newly formed CDMO, focused on finished doses and solid forms. Astrea Pharma’s first production site is located in Fontaine-lès-Dijon (France).
In 2022, Groupe Chevrillon invested in Astrea Pharma, a newly formed CDMO, focused on finished doses and solid forms. Astrea Pharma’s first production site is located in Fontaine-lès-Dijon (France).
